长药控股(300391) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥785,147,049.48, representing a 525.52% increase compared to ¥125,518,776.48 in the same period last year[6] - Net profit attributable to shareholders was ¥59,407,361.17, a significant increase of 1,276.73% from a loss of ¥5,048,517.31 in the previous year[6] - The net profit after deducting non-recurring gains and losses was ¥54,982,979.56, up 640.74% from a loss of ¥10,168,067.14 in the same period last year[6] - Basic earnings per share rose to ¥0.1696, compared to a loss of ¥0.0144 in the same period last year, marking an increase of 1,277.78%[6] - The weighted average return on net assets improved to 7.37%, compared to -0.62% in the previous year, reflecting an increase of 1,288.71%[6] - The company reported a net loss of CNY 322,516,223.10, an improvement from a loss of CNY 381,923,583.27 in the previous period[36] - The company reported a total comprehensive income of ¥106,268,532.66 for Q1 2021, compared to a loss of ¥1,593,584.39 in the same period last year[44] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,769,078,942.55, a 1.84% increase from ¥4,683,035,941.29 at the end of the previous year[6] - The company's current assets totaled CNY 2,253,596,420.54, up from CNY 2,118,734,418.30 at the end of 2020, indicating an increase of about 6.34%[33] - The total liabilities as of the end of Q1 2021 amounted to ¥1,534,909,708.35, with total equity at ¥914,625,011.16[42] - The total liabilities decreased slightly to CNY 3,213,097,827.55 from CNY 3,233,554,499.76, a reduction of approximately 0.63%[35] - The company's equity attributable to shareholders increased to CNY 836,340,779.74 from CNY 776,694,642.74, reflecting a growth of about 7.68%[36] Cash Flow - The company reported a net cash flow from operating activities of -¥36,074,307.49, which is a decline of 456.62% compared to -¥6,480,908.22 in the same period last year[6] - Cash inflow from operating activities amounted to 774,178,788.15, a significant increase from 90,024,547.26 in the previous period[50] - Cash outflow from operating activities totaled 810,253,095.64, leading to a net cash flow from operating activities of -36,074,307.49[51] - The cash flow from investing activities resulted in a net outflow of -21,671,475.69, compared to a net inflow of 1,299,441.36 in the previous period[51] - Cash flow from financing activities generated a net inflow of 8,179,398.42, contrasting with a net outflow of -20,447,708.57 in the previous period[52] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,582[10] - The largest shareholder, Shenzhen Shengshi Fenghua Enterprise Management Co., Ltd., held 29.90% of the shares, totaling 104,750,500 shares[10] Operational Insights - The inclusion of Changjiang Star into the consolidation scope in December 2020 was a major factor driving revenue growth[17] - The top five suppliers accounted for 34.71% of total procurement, with the largest supplier contributing 14.01%[17] - The top five customers represented 35.27% of total sales, with the largest customer accounting for 10.12%[18] - The company plans to raise up to 140 million yuan through a simplified procedure for issuing shares to specific targets[24] - The annual operational plan was executed without significant changes, focusing on market expansion and new product development[18] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[43] Inventory and Receivables - The company reported accounts receivable of 1.24 billion yuan, which constituted 54.85% of current assets, indicating potential cash flow pressure[19] - Inventory at the end of the reporting period was 195.09 million yuan, making up 8.66% of current assets, primarily due to increased sales volume[20] - Accounts receivable rose to CNY 1,236,208,740.17 from CNY 1,190,839,098.78, marking an increase of about 3.81%[33] - Inventory decreased to CNY 195,090,071.62 from CNY 251,605,421.28, indicating a decline of about 22.5%[33] Research and Development - Research and development expenses for Q1 2021 were ¥10,940,213.27, up from ¥7,613,057.11 in Q1 2020, reflecting a focus on innovation[42] Audit Information - The company did not undergo an audit for the first quarter report[57]